Thierry Andre, MD

Thierry André, MD, is a professor of Medical Oncology at the Sorbonne Université and head of the Medical Oncology Department at the Saint Antoine Hospital in Paris, France.

Articles

Dr André on the Safety Profile of Nivolumab/Ipilimumab in MSI-H/dMMR Metastatic CRC

May 1st 2025

Thierry André, MD, discusses the safety profile of nivolumab/ipilimumab for the treatment of patients with MSI-H/dMMR metastatic colorectal cancer.

Dr André on Nivolumab Plus Ipilimumab in MSI-H/dMMR mCRC

January 29th 2025

Thierry André, MD, discusses the efficacy of nivolumab plus ipilimumab vs nivolumab monotherapy in MSI-H/dMMR mCRC.

Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups

September 16th 2024

Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Dr Andre on the SOLSTICE Trial in mCRC

July 21st 2023

Thierry Andre, MD, discusses the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer and the safety profiles of the 2 arms of the phase 3 SOLSTICE trial.

Dr Andre on Survival Results From the SOLSTICE Trial in mCRC

June 6th 2023

Thierry Andre, MD, discusses negative overall survival results and updated safety data from the phase 3 SOLSTICE trial in metastatic colorectal cancer.

Dr. Andre on the Rationale for the KEYNOTE-177 Trial in mCRC

June 3rd 2020

Thierry Andre, MD, discusses the rationale for the phase 3 KEYNOTE-177 trial in metastatic colorectal cancer.

Dr. Andre Discusses the Future of Immunotherapy in mCRC

February 20th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the future of immunotherapy for patients with metastatic colorectal cancer.

Dr. Andre on Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC

January 25th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the results of the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.